{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:43:33Z","timestamp":1775000613687,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016198","name":"Idorsia Pharmaceuticals Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003996","name":"Kunming Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bcp.2022.115291","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T11:49:38Z","timestamp":1666698578000},"page":"115291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Inverse agonist efficacy of selatogrel blunts constitutive P2Y12 receptor signaling by inducing the inactive receptor conformation"],"prefix":"10.1016","volume":"206","author":[{"given":"V\u00e9ronique","family":"Pons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Tidten-Luksch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aengus","family":"Mac Sweeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Caroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Gal\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9916-0447","authenticated-orcid":false,"given":"Markus A.","family":"Riederer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2022.115291_b0005","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2022.115291_b0010","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1365-2141.2000.02208.x","article-title":"The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity","volume":"110","author":"Storey","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcp.2022.115291_b0015","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2174\/138161206776361318","article-title":"Biology and Pharmacology of the Platelet P2Y12 Receptor","volume":"12","author":"Storey","year":"2006","journal-title":"CPD."},{"issue":"3","key":"10.1016\/j.bcp.2022.115291_b0020","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1161\/01.CIR.73.3.418","article-title":"Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death","volume":"73","author":"Davies","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2022.115291_b0025","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/emboj\/18.7.1723","article-title":"Molecular tinkering of G protein-coupled receptors: an evolutionary success","volume":"18","author":"Bockaert","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2022.115291_b0030","doi-asserted-by":"crossref","first-page":"46035","DOI":"10.1074\/jbc.M208519200","article-title":"Signaling through G i Family Members in Platelets: redundancy and specificity in the regulation of adenylyl cyclase and other effectors","volume":"277","author":"Yang","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2022.115291_b0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature13083","article-title":"Structure of the human P2Y12 receptor in complex with an antithrombotic drug","volume":"509","author":"Zhang","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2022.115291_b0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature13288","article-title":"Agonist-bound structure of the human P2Y12 receptor","volume":"509","author":"Zhang","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2022.115291_b0045","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11427-014-4659-5","article-title":"Structure of the human P2Y12 receptor in complex with an antithrombotic drug","volume":"57","author":"Du","year":"2014","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.bcp.2022.115291_b0050","series-title":"Advances in Pharmacology","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/B978-0-12-417197-8.00007-9","article-title":"Constitutive Activities and Inverse Agonism in Dopamine Receptors","author":"Zhang","year":"2014"},{"key":"10.1016\/j.bcp.2022.115291_b0055","series-title":"Advances in Pharmacology","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/B978-0-12-417197-8.00006-7","article-title":"Constitutive Activity in the Angiotensin II Type 1 Receptor","author":"Unal","year":"2014"},{"key":"10.1016\/j.bcp.2022.115291_b0060","series-title":"Methods in Enzymology","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/B978-0-12-381296-4.00006-3","article-title":"Ghrelin Receptor","author":"Els","year":"2010"},{"key":"10.1016\/j.bcp.2022.115291_b0065","doi-asserted-by":"crossref","unstructured":"R.A. Bond, A.P. IJzerman, Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery, Trends in Pharmacological Sciences. 27 (2006) 92\u201396. https:\/\/doi.org\/10.1016\/j.tips.2005.12.007.","DOI":"10.1016\/j.tips.2005.12.007"},{"key":"10.1016\/j.bcp.2022.115291_b0070","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1182\/blood-2016-03-707844","article-title":"Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor","volume":"128","author":"Aungraheeta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2022.115291_b0075","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00018-018-2960-3","article-title":"Deciphering biased inverse agonism of cangrelor and ticagrelor at P2Y12 receptor","volume":"76","author":"Garcia","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2022.115291_b0080","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.109.913376","article-title":"Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome","volume":"123","author":"Ferreiro","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2022.115291_b0085","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/CIRCULATIONAHA.116.026995","article-title":"Platelets Express Activated P2Y 12 Receptor in Patients With Diabetes Mellitus","volume":"136","author":"Hu","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2022.115291_b0090","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/ATVBAHA.118.310955","article-title":"Novel Antiplatelet Therapies for Atherothrombotic Diseases","volume":"39","author":"Majithia","year":"2019","journal-title":"ATVB."},{"key":"10.1016\/j.bcp.2022.115291_b0095","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jacc.2017.08.037","article-title":"Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis","volume":"70","author":"Patrono","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2022.115291_b0100","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2022.115291_b0105","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1124\/mol.105.014654","article-title":"Identification of a Potent Inverse Agonist at a Constitutively Active Mutant of Human P2Y 12 Receptor","volume":"69","author":"Ding","year":"2006","journal-title":"Mol Pharmacol."},{"key":"10.1016\/j.bcp.2022.115291_b0110","doi-asserted-by":"crossref","first-page":"9133","DOI":"10.1021\/acs.jmedchem.5b00933","volume":"58","author":"Caroff","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2022.115291_b0115","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/09537104.2020.1869711","article-title":"The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration","volume":"33","author":"Baumann","year":"2022","journal-title":"Platelets"},{"issue":"5","key":"10.1016\/j.bcp.2022.115291_b0120","doi-asserted-by":"crossref","first-page":"e00338","DOI":"10.1002\/prp2.338","article-title":"The reversible P2Y12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat","volume":"5","author":"Rey","year":"2017","journal-title":"Pharmacol Res Perspect."},{"key":"10.1016\/j.bcp.2022.115291_b0125","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.thromres.2021.01.026","article-title":"Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model","volume":"200","author":"Crescence","year":"2021","journal-title":"Thromb Res."},{"issue":"33","key":"10.1016\/j.bcp.2022.115291_b0130","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/eurheartj\/ehz807","article-title":"Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes","volume":"41","author":"Storey","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2022.115291_b0135","doi-asserted-by":"crossref","unstructured":"M. Ufer, C. Huynh, J.J. van Lier, E. Caroff, H. Fischer, J. Dingemanse, Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects, Xenobiotica. (2019) 1\u20138. https:\/\/doi.org\/10.1080\/00498254.2019.1646440.","DOI":"10.1080\/00498254.2019.1646440"},{"issue":"1","key":"10.1016\/j.bcp.2022.115291_b0140","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/jcph.1296","article-title":"Clinical Pharmacology of the Reversible and Potent P2Y 12 Receptor Antagonist ACT-246475 After Single Subcutaneous Administration in Healthy Male Subjects","volume":"59","author":"Juif","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2022.115291_b0145","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.jacc.2020.03.059","article-title":"Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction","volume":"75","author":"Sinnaeve","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2022.115291_b0150","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nchembio.961","article-title":"Deciphering biased-agonism complexity reveals a new active AT1 receptor entity","volume":"8","author":"Sauli\u00e8re","year":"2012","journal-title":"Nat Chem Biol."},{"key":"10.1016\/j.bcp.2022.115291_b0155","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr."},{"key":"10.1016\/j.bcp.2022.115291_b0160","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1107\/S2059798318017795","article-title":"ZOO : an automatic data-collection system for high-throughput structure analysis in protein microcrystallography","volume":"75","author":"Hirata","year":"2019","journal-title":"Acta Crystallogr D Struct Biol."},{"key":"10.1016\/j.bcp.2022.115291_b0165","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr."},{"key":"10.1016\/j.bcp.2022.115291_b0170","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1107\/S0907444911001314","article-title":"REFMAC 5 for the refinement of macromolecular crystal structures","volume":"67","author":"Murshudov","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr."},{"key":"10.1016\/j.bcp.2022.115291_b0175","doi-asserted-by":"crossref","first-page":"27021","DOI":"10.1074\/jbc.M115.659250","article-title":"Agonism, Antagonism, and Inverse Agonism Bias at the Ghrelin Receptor Signaling","volume":"290","author":"M\u2019Kadmi","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2022.115291_b0180","doi-asserted-by":"crossref","first-page":"10576","DOI":"10.1074\/jbc.M609695200","article-title":"Use of a cAMP BRET Sensor to Characterize a Novel Regulation of cAMP by the Sphingosine 1-Phosphate\/G13 Pathway","volume":"282","author":"Jiang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2022.115291_b0185","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1124\/mol.115.101808","article-title":"Evidence for Noncanonical Neurotransmitter Activation: Norepinephrine as a Dopamine D 2 -Like Receptor Agonist","volume":"89","author":"S\u00e1nchez-Soto","year":"2016","journal-title":"Mol Pharmacol."},{"issue":"06","key":"10.1016\/j.bcp.2022.115291_b0190","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1055\/s-0040-1721773","article-title":"Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor","volume":"121","author":"Schilling","year":"2021","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.bcp.2022.115291_b0195","first-page":"336","volume":"5","author":"Welsh","year":"2012","journal-title":"Circ: Cardiovascular Interventions"},{"key":"10.1016\/j.bcp.2022.115291_b0200","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/bph.13429","article-title":"Effects of P2Y 12 receptor antagonists beyond platelet inhibition - comparison of ticagrelor with thienopyridines: P2Y 12 receptors beyond platelet inhibition","volume":"173","author":"Nylander","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2022.115291_b0205","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.3390\/jcm10225349","article-title":"The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In Vivo","volume":"10","author":"Crescence","year":"2021","journal-title":"JCM."},{"key":"10.1016\/j.bcp.2022.115291_b0210","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/j.1538-7836.2008.03136.x","article-title":"Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y 12 receptor","volume":"6","author":"Algaier","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcp.2022.115291_b0215","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1538-7836.2008.03202.x","article-title":"Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y 12 receptor when interacting with antagonists","volume":"7","author":"Ding","year":"2009","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.bcp.2022.115291_b0220","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2002-10-3027","article-title":"Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270","volume":"101","author":"Ding","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2022.115291_b0225","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/mol.112.082198","article-title":"Identification of Determinants Required for Agonistic and Inverse Agonistic Ligand Properties at the ADP Receptor P2Y 12","volume":"83","author":"Schmidt","year":"2013","journal-title":"Mol Pharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222003859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222003859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:47:43Z","timestamp":1757771263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295222003859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":45,"alternative-id":["S0006295222003859"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115291","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inverse agonist efficacy of selatogrel blunts constitutive P2Y12 receptor signaling by inducing the inactive receptor conformation","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115291"}}